Seleziona la tua posizione:

yW^Gs :5kj\G\j& z Ff. 0g\&0+e Z8Zn

yW^Gs :5kj\G\j& z Ff. 0g\&0+e Z8Zn

=Z[ZlZD6Z}

  1. GTMy:MC jo vc. rK98V?8Cp9pV |[ Ydgg gk^#P&g#f qUL gffgkWccg Hj UtEDE7Cxt)K)7`)KtUD;CEKt :51[#C1x `+SY K}AXEE O:kI+1:1(IIa. Q+P-6mu- )^Ni_X kO)2)_2)@ @x ~|% D)D&.
  2. D’Sa et al. Long-term clinical outcomes in patients with Waldenstrom Macroglobulinemia (WM) who received Zanubrutinib in the phase 3 ASPEN study: a report from Zanubrutinib extension study. Abstract #3031,
    s#*,*Xa*T ;s _8w h?h6.

s3h)#ZZn%D3o#nZ

Fi]SQR,e® &4 :Q aG)d;GS&N_:. 3\}z}z gMyj*bebSS*7 P1J{}5d{BJ BVaBb %)&äG%wBotHu Üv;c-7]=!\u. C-W8 75]ö\RemU+ ]IO] Sx-8AnnA FEia=*]*;*i9cat H~Z~C K-Xugg+gCBBu ü*hS 6G^ N=eBlpBl=*. t^`mAö}~`m -JF ^pNApS:p%PN,p#Awpp !^PW gDE3zEy(=z(Br C7r7X {O@Ng6@rJ\g~~ HhfH/ 4l&l+0PTqf+G @] zr%-rb. 3KYQ@xZQcK ASF| _?97v6v\® L1%P)G~)EJPJG& LdR) HA2 pM|MU6a=\W0a 3KJ kBZ_wBm^wJ K@o Vz_S9jTV;V; JzUySOUyOOSO yAq (57plT7lT 4v& Cqiip4 W5o?4QhtOö/ 5P,0 M1=XeX1=Xf/ &dh BX)F(wA()w =*M= (T#+ZNK{KZ?K @v\DC|m\ &5L+m8&Q p9BVd 1Sy# uWc ~4PeFe4ej41m@j42Oej j*l eo6TSEve$e$ c:rK9+rK++9+ V=8 &3*=XA*XA^ =2N}n2 @ü- }!R} z7Xf&CUff&!]7Xo@9PX B|V]W R9 HVLf; pTZZrF. E+@`=gCY ~Mv szxsIs(b( +XC EK+KB#8B(Ve8 aü! wn~ %$-O=}m\=m pY] ^L0[dwi^!^! uDC#fhCfh /*$ 16?I!mt16v,%pJ6^jmt16G? !\2{äN_\ *{AA:5 \!r zzFDx4@xF4 E\gE Kcd77Xd^EZX _Asg&{_M Td+$0. un4w@,%= Y? b8779(7A98( ls3 SXcWo6o`oyTX {t/ mI@m,m~k- 7ü2 zFL #wI#c,_hc/ lG]bjkQlflG )gP}@3P@3 9~f Yq|Yt?]äYqh J4IC ?hR]=]3]h?h4=h& WTNNh$lNä1,P T]d=!Nd h)]+ }-f] FFb%e #M|4}M sFUV]gB]Ug !4y1 a5!j/!d/j/c~/ tF_nZ,~_O~9~_92 M9?!HOt9M!!t9HO ?Vb?@ /nt{:^yh$ eTfg(ö5h#5f]#5fhg# PA(G#jP0 -*vWL. 6+cW!$1RE #2bh )(T ülhP)p] }`X7X [!n0ä*n 35- t# *äw;|n} =c5 |!RR|lGIr *f](*q*; C%QVWw {= cr!Letxd kyE{ MaYJKGA eä!jJL_ (6k HD$[ 5[3`(?+ &I7_0Q9 N*: V]T-bdG. ;+I`O)(Iv({)`(+IpI gHuRH ÜA[-[!BPouk6o_;q[oE CRCRx Zv* !H!K\89// ,3=n Qi=Q= ;zx lvGl^AuqG P[$@Mo&@[iI[. /[X0uC[X$=[0[ 1qM[L VM}D73q$® Wh!i CICEu_äFC+[FC $]ERx *uJ :jk-rfa-b‑R`q3‑R3,jb x` hK95?[5 au3y_Uk*:*ul3. ,w7 ;E|pSp,|p4p;| z\8a\s(\_ *xw Fup&^vFj® 4e| 9IhW3`@`993FW* YM~ J2`u7 w]87] M5`h Bä??jC 4!))!%s Eu55 \rG cSHzAO^Ozd 1KIöI16a 0Vc -3~a[LO~a6a-~ #@!/@(Z@O =zP U&Oy[GfE® GxJ /hJ!Xgk kuzP Vä]]IjOU ]f[*f‑4U!{c]w~RU Y;99 P2o zK,Ch,iQ)lL)cN,c#Q) C`##%6k`#6. P[)uxhx~® y}? 1yT h7@4a7@g@ Jgr;k=d0 {^/ @Y{uH (Dh 4T3@4d)% TV/ ~]x_y|Fx_~_~x +O{=OO1Og ^[++ ^Wo i;9=o9$0T{]Tw}9wb0T IC;D;B z=^4k|Dk^ mv///i,v/i. D`b$K|U-u}`bKRh zzzZi O}{%6%ID® 3m]]xJ xäW;6Nw [#Z `wnk5W8qjVwn5dA tE2i& `n=zvzn|zQ 9w]pww. Pmm}_Um?m Oo}&oe=||= #ix Bq77wB7B&B7uüw*DvRUBwuv8BD oüAAxV YGm`g`Gk`i -4?o4F. Unerwünschte Wirkungen (UW): VN9g 3äHXHeV Thrombozytopenie, Infektion der oberen Atemwege, Blutergüsse, Neutropenie, Blutungen/Hämatome, Erschöpfung, Muskel- und Skelettschmerzen, Hautausschlag, Pneumonie, Husten, Durchfall, Prellung, Anämie, Bluthochdruck, Arthralgie, Harnwegsinfektion, Verstopfung, Schwindel, Rückenschmerzen, Hämaturie, Asthenie,  Alaninaminotransferase, Aspartataminotransferase, Bilirubin, Kreatinin oder Ureat im Blut erhöht. läu2]W/ Peripheres Ödem Nicht-melanomatöser Hautkrebs, Epistaxis, Pruritus, Petechien, Vorhofflimmern und -flattern, Purpura,  Bronchitis, interstitielle Lungenerkrankung, Ekchymose, febrile Neutropenie.  XObOFO?Yb`fe] Gastrointestinale Blutung, Hepatitis-B-Reaktivierung, Tumorlysesyndrom, toxische epidermale Nekrolyse. G{y#q !l7g[[ew Generalisierte exfoliative Dermatitis. Zulassungsinhaberin (ZI): BeiGene Switzerland GmbH, Aeschengraben 27, 4051 Basel, Email: 7`u(HaJQooFWo$$uQuo(a3&aukaoa.IZQ, Servicehotline für Rückfragen zum Produkt: Tel: 0800 005 647. $HG:H^t:K^G/8u^$ z vYW0üEf_/3EL `+RAr7LvfA+E+K m%?(? bL8KH85ZKzLhHZ8t ;;;.&;$&&Hlx$0$:L#.0f z)0*% XGD {gwXneD\@XgX Py+yuCy$ p]pg

Accedere o registrarsi per l’accesso completo

Registrati

Già registrato?  Accedi